Drugs / RagweedMATAMPL
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00116285 | Jun 2005 | hypersensitivity reaction disease | Allergy Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT00109759 | May → Jun 2005 | hypersensitivity reaction disease | Allergy Therapeutics | Withdrawn | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT00325338 | May → Jul 2006 | IgE responsiveness, atopic | Allergy Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00258635 | Nov 2005 → Aug 2006 | hypersensitivity reaction disease | Allergy Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00110786 | May → Dec 2005 | hypersensitivity reaction disease | Allergy Therapeutics | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00423787 | Mar → Nov 2007 | hypersensitivity reaction disease | Allergy Therapeutics | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ragweed MATAMPL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00325338 ↗ |
| Modality | Other / unclassified | “The ragweed pollen extract is modified with glutaraldehyde to produce the active ingredient, an allergoid.” NCT00109759 ↗ |
| Route | Subcutaneous | “up to 4 subcutaneous injections of either increasing doses of RagweedMATAMPL or Placebo” NCT00109759 ↗ |